马雷克斯集团

最新新闻

• 评级变动
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 公司公告
  Shanghai Mecan Pharma Co., Ltd. voluntarily discloses an announcement regarding the approval granted to MRX-5 in the United States to commence clinical trials.
  SZSI · 2026/1/29
• Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $86
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• UBS Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 公司公告
  Mengke Pharmaceutical: Shanghai Mengke Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Approval Granted to MRX-5 in the United States to Conduct Clinical Trials
  SZSI · 2026/1/29
• 评级变动
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $76
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 公司公告
  Shanghai Mengke Pharmaceutical Co., Ltd. voluntarily disclosed the announcement on the successful completion of the MRX-4 phase III clinical trial for injectable use in China
  SZSI · 2024/11/28
• 评级变动
  TD Cowen Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $67
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 公司公告
  Announcement on voluntary disclosure of MRX-5 Australian Phase I clinical trial results by Shanghai Mengke Pharmaceutical Co., Ltd.
  SZSI · 2024/10/25
• Piper Sandler Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2026/10/2
• Form 144 | Marex Group(MRX.US) Officer Proposes to Sell 5.34 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 公司公告
  Shanghai Mengke Pharmaceutical Co., Ltd. voluntarily disclosed the announcement that the MRX-5 clinical trial application was approved
  SZSI · 2025/1/4
• 评级变动
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $76
  \u5e02\u573a\u8d44\u8baf · 2026/7/9
• 评级变动
  Barclays Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Piper Sandler Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $75
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  TD Cowen Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $75
  \u5e02\u573a\u8d44\u8baf · 2026/6/8
• 评级变动
  KBW Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  KBW Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $80
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 评级变动
  Goldman Sachs Maintains Marex Group(MRX.US) With Buy Rating, Raises Target Price to $62
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• KBW Maintains Marex Group(MRX.US) With Buy Rating, Maintains Target Price $90
  \u5e02\u573a\u8d44\u8baf · 2026/8/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。